Caribou Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 15, 2023, covers the results of Caribou Biosciences, Inc.'s Annual Meeting of Stockholders held on that date. The company is incorporated in Delaware and trades on the NASDAQ Global Select Market under the symbol CRBU.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes and Voting Results
The following proposals were submitted to and voted upon by stockholders:
- Proposal 1: Election of Directors Three nominees were elected to serve as Class II directors until the 2026 annual meeting:
- Andrew Guggenheim, M.B.A.: 31,032,443 votes for; 5,325,715 votes withheld.
- David L. Johnson, M.B.A.: 31,840,467 votes for; 4,517,691 votes withheld.
- Nancy Whiting, Pharm.D.: 31,863,074 votes for; 4,495,084 votes withheld.
- Proposal 2: Ratification of Auditors Stockholders ratified the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Votes For: 45,652,597
- Votes Against: 51,771
- Votes Abstain: 82,435
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to report the outcome of the shareholder vote.
Key Facts for Investor Verification
- Confirmation of the newly elected board members and their term expiration (2026).
- Verification of the ratification of Deloitte & Touche LLP as the external auditor.
- Review of the definitive proxy statement (Schedule 14A) filed on April 28, 2023, for detailed background on the proposals.